Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taselisib - Genentech/Chugai Pharmaceutical

Next Previous
Drug Profile

Taselisib - Genentech/Chugai Pharmaceutical

Alternative Names: GDC 0032; RG-7604

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Netherlands Cancer Institute
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Benzazepines; Oxazepines; Pyrazoles; Small molecules; Triazoles
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 12 Jul 2022 Roche terminates a phase III SANDPIPER trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in US, Australia, Austria, Bosnia and Herzegovina, Bulgaria, Canada, China, Colombia, Czech Republic, Finland, France, Germany, Greece, Italy, Mexico, the Netherlands, Peru, Poland, Portugal, Romania, Russia, Serbia, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (PO) due to modest clinical benefit and limited tolerability(NCT02340221) (EudraCT2014-003185-25)
  • 01 May 2022 The Netherlands Cancer Institute and Genentech completes a phase I/II trial in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in France, Netherlands, Spain and United Kingdom (NCT02285179)
  • 24 Sep 2021 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top